收费全文 | 215765篇 |
免费 | 29017篇 |
国内免费 | 7510篇 |
耳鼻咽喉 | 1707篇 |
儿科学 | 1694篇 |
妇产科学 | 5162篇 |
基础医学 | 15643篇 |
口腔科学 | 2185篇 |
临床医学 | 17284篇 |
内科学 | 22313篇 |
皮肤病学 | 1378篇 |
神经病学 | 1225篇 |
特种医学 | 6223篇 |
外国民族医学 | 270篇 |
外科学 | 30676篇 |
综合类 | 28603篇 |
现状与发展 | 39篇 |
一般理论 | 3篇 |
预防医学 | 10124篇 |
眼科学 | 121篇 |
药学 | 15394篇 |
146篇 | |
中国医学 | 5677篇 |
肿瘤学 | 86425篇 |
2024年 | 526篇 |
2023年 | 4325篇 |
2022年 | 7791篇 |
2021年 | 11511篇 |
2020年 | 10738篇 |
2019年 | 9703篇 |
2018年 | 9278篇 |
2017年 | 9783篇 |
2016年 | 10533篇 |
2015年 | 12124篇 |
2014年 | 17542篇 |
2013年 | 17579篇 |
2012年 | 14048篇 |
2011年 | 14281篇 |
2010年 | 10413篇 |
2009年 | 10606篇 |
2008年 | 10936篇 |
2007年 | 10417篇 |
2006年 | 9114篇 |
2005年 | 7532篇 |
2004年 | 6236篇 |
2003年 | 5197篇 |
2002年 | 4440篇 |
2001年 | 4117篇 |
2000年 | 3501篇 |
1999年 | 2925篇 |
1998年 | 2465篇 |
1997年 | 2174篇 |
1996年 | 1806篇 |
1995年 | 1728篇 |
1994年 | 1437篇 |
1993年 | 1090篇 |
1992年 | 947篇 |
1991年 | 886篇 |
1990年 | 670篇 |
1989年 | 616篇 |
1988年 | 522篇 |
1987年 | 434篇 |
1986年 | 311篇 |
1985年 | 401篇 |
1984年 | 343篇 |
1983年 | 220篇 |
1982年 | 227篇 |
1981年 | 206篇 |
1980年 | 186篇 |
1979年 | 123篇 |
1978年 | 82篇 |
1977年 | 74篇 |
1976年 | 65篇 |
1975年 | 41篇 |
![点击此处可从《Journal of pineal research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
![点击此处可从《NMR in biomedicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Context
Family caregivers constitute a critical component of the end-of-life care system with considerable cost to themselves. However, the joint association of terminally ill cancer patients' symptom distress and functional impairment with caregivers' subjective caregiving burden, quality of life (QOL), and depressive symptoms remains unknown.Objectives/Methods
We used multivariate hierarchical linear modeling to simultaneously evaluate associations between five distinct patterns of conjoint symptom distress and functional impairment (symptom-functional states) and subjective caregiving burden, QOL, and depressive symptoms in a convenience sample of 215 family caregiver–patient dyads. Data were collected every 2 to 4 weeks over patients' last 6 months.Results
Caregivers of patients in the worst symptom-functional states (States 3–5) reported worse subjective caregiving burden and depressive symptoms than those in the best two states, but the three outcomes did not differ between caregivers of patients in State 3 and States 4–5. Caregivers of patients in State 5 endured worse subjective caregiving burden and QOL than those in State 4. Caregivers of patients in State 4 suffered worse subjective caregiving burden and depressive symptoms but comparable QOL to those in State 2.Conclusion
Patients' five distinct, conjoint symptom-functional states were significantly and differentially associated with their caregivers' worse subjective caregiving burden, QOL, and depressive symptoms while caring for patients over their last 6 months. 相似文献Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
Areas covered: This review first focuses on the clinical trials evaluating the efficacy and tolerability of nab-paclitaxel in NSCLC at different settings. The approval of nab-paclitaxel in combination with carboplatin at the front-line setting for advanced NSCLC was based on the key phase III study, which showed that nab-paclitaxel/carboplatin was associated with superior overall response rate and favorable toxicity profile compared to sb-paclitaxel/carboplatin. The review also addresses the nab-paclitaxel pharmacology, other combinations (e.g. immunotherapy with PD-1/PD-L1 inhibitors), potential biomarkers (e.g. caveolin-1), and special subgroups (e.g. the elderly, squamous histology).
Expert opinion: Existing data has established the role of nab-paclitaxel in the management of advanced NSCLC. Emerging evidence, such as preliminary results from Keynote-407 and IMpower 131 studies, indicates that novel combinations of nab-paclitaxel/carboplatin and PD-1/PD-L1 inhibitors could further improve clinical benefits with manageable toxicity. Nevertheless, in order to better position nab-paclitaxel and to improve patient selection, future studies are warranted to further understand its mechanism of action, predictive biomarkers, and potential synergism with other agents. 相似文献